Sutent is a kinase inhibitor indicated for the treatment of:
- Gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate.
- Advanced renal cell carcinoma (RCC).
- Progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unresectable locally advanced or metastatic disease.
- Adult patients at high risk of recurrent RCC following nephrectomy.